The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder.

Heather N Palis, Scott MacDonald
Author Information
  1. Heather N Palis: Department of Psychiatry, University of British Columbia, Vancouver, BC.
  2. Scott MacDonald: Providence Health Care, Vancouver, BC.

Abstract

No abstract text available.

References

  1. Cochrane Database Syst Rev. 2016 Sep 27;9:CD007380 [PMID: 27670244]
  2. CMAJ. 2023 Oct 10;195(39):E1356 [PMID: 37816525]
  3. Addiction. 2019 Jan;114(1):9-15 [PMID: 29900624]
  4. Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255 [PMID: 32601988]
  5. Ann N Y Acad Sci. 2022 Feb;1508(1):3-22 [PMID: 34561865]
  6. Subst Abuse Treat Prev Policy. 2022 Aug 26;17(1):62 [PMID: 36028837]
  7. JAMA Psychiatry. 2023 Jan 1;80(1):31-39 [PMID: 36383348]
  8. J Epidemiol Community Health. 2020 Nov;74(11):964-968 [PMID: 32535550]
  9. CMAJ. 2023 Jul 17;195(27):E934-E935 [PMID: 37460124]
  10. PLoS One. 2021 May 26;16(5):e0252090 [PMID: 34038452]
  11. CMAJ. 2023 Oct 10;195(39):E1354 [PMID: 37816523]
  12. CMAJ. 2023 Oct 10;195(39):E1355 [PMID: 37816522]
  13. Front Psychiatry. 2022 Dec 02;13:1074691 [PMID: 36532164]
  14. J Addict Med. 2020 Dec;14(6):e287-e289 [PMID: 33009167]

MeSH Term

Humans
Central Nervous System Stimulants
Attention Deficit Disorder with Hyperactivity

Chemicals

Central Nervous System Stimulants